Loading
A South Korean study building a multi-cancer blood test from whole-genome sequencing of circulating DNA.
Yonsei whole-genome cell-free DNA multi-cancer platform study (NCT06231953) is an observational study sponsored by Yonsei University. It aims to establish a multi-cancer early detection platform through whole-genome sequencing of circulating DNA.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 4,000 participants, a start on 13 October 2022 and primary completion expected in December 2026.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/